导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.99% | 3400/4763 |
| 近一周 | -5.26% | 5312/5452 |
| 近一月 | -3.21% | 2264/5409 |
| 近一季 | -10.58% | 3772/5219 |
| 近半年 | -14.07% | 3947/4908 |
| 近一年 | 20.78% | 484/4388 |
| 近两年 | 116.62% | 455/2951 |
| 近三年 | 82.28% | 225/2250 |
| 成立以来 | 124.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.65% 873/4961 |
-6.50% 3706/5312 |
- - |
- - |
| 2025 | 100.13% 20/4813 |
10.91% 288/3635 |
5.47% 585/4076 |
46.48% 532/4524 |
16.78% 27/4813 |
| 2024 | 4.02% 1898/3463 |
10.56% 53/2808 |
-5.55% 1744/3014 |
12.26% 2384/3129 |
-11.26% 3024/3463 |
| 2023 | -11.11% 1371/2656 |
5.61% 767/2280 |
-8.04% 1952/2385 |
-4.30% 1107/2515 |
-4.37% 986/2655 |
| 2022 | -21.24% 1022/2207 |
-7.95% 264/1919 |
5.78% 826/2016 |
-17.15% 1557/2113 |
-2.38% 1802/2208 |
| 2021 | 32.17% 59/1822 |
-1.02% 419/1255 |
11.95% 354/1330 |
21.81% 38/1466 |
-2.07% 1399/1822 |
| 2020 | 40.54% 309/1250 |
-13.22% 924/1028 |
12.20% 694/1067 |
8.97% 688/1164 |
32.45% 16/1184 |
| 2019 | 28.35% 522/1092 |
21.35% 601/754 |
-3.07% 374/804 |
-3.41% 738/850 |
12.98% 32/918 |
| 2018 | -39.67% 611/834 |
- - |
- - |
- - |
-14.71% 592/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证申万有色金属ETF VS. 长安沪深300非周期A(740101) |